Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma

PURPOSE: The phase III CELESTIAL study demonstrated improved overall survival (OS) and progression-free survival (PFS) with cabozantinib versus placebo in patients with previously treated, advanced hepatocellular carcinoma (HCC). We analyzed outcomes by baseline alpha-fetoprotein (AFP) and on-treatm...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clin Cancer Res
Hlavní autoři: Kelley, Robin Kate, Meyer, Tim, Rimassa, Lorenza, Merle, Philippe, Park, Joong-Won, Yau, Thomas, Chan, Stephen L., Blanc, Jean-Frederic, Tam, Vincent C., Tran, Albert, Dadduzio, Vincenzo, Markby, David W., Kaldate, Rajesh, Cheng, Ann-Lii, El-Khoueiry, Anthony B., Abou-Alfa, Ghassan K.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2020
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7779341/
https://ncbi.nlm.nih.gov/pubmed/32636319
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-3884
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky